
|Articles|May 15, 2004
Moderate glaucoma best served by aggressive IOP-lowering efforts
London-The Early Manifest Glaucoma Trial (EMGT) provides a unique set of data for the natural history of moderate glaucoma and demonstrates that lowering IOP by 25% protects against progression of visual field loss, according to Roger A. Hitchings, MD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Optigo: Lead anti-VEGF program advancing toward IND-enabling studies
2
AAO 2025: Advancements in laser refractive surgery
3
From then to next: Five decades of transformation in ophthalmology
4
Opus Genetics has Type B RMAT meeting with FDA for its gene therapy candidate, OPGx-LCA5
5


















































.png)


